Interview with Dr. Jordi Remon - thymic cancer and the PECATI trial

8 Views

07/18/23

Thymic tumors are rare, effecting only 0.13 per 100,000 individuals. These tumors, also called thymic epithelial tumors (TETs), are cancers that can form in the cells that cover the outside surface of the thymus, a small organ that lies in the upper chest above the heart and under the breastbone. MEDSIR's PECATI trial is a single arm, phase II trial that is evaluating the efficacy of combining Lenvatinib and pembrolizumab for patients with advanced thymic tumors.

https://www.medsir.org/pecati-clinical-trial
https://www.medsir.org/
https://www.medsir.org/contact

#thymiccancer #clinicaltrials #oncology #clinicalresearch #immunotherapy